SCHEMBL552069

SCHEMBL552069

CC(C)(C)OC(=O)N1CCc2ccccc21

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.61
RAB9A P51151 3/20 0.57
NPC1 O15118 2/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
TSHR P16473 2/20 0.55
ALDH1A1 P00352 6/20 0.55
MAPT P10636 2/20 0.55
HPGD P15428 2/20 0.54
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
NPSR1 Q6W5P4 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.52
POLB P06746 1/20 0.52
KDM1A O60341 1/20 0.52
SIGMAR1 Q99720 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30900483 1.00 NOTUM (0.61) NOTUMRAB9ANPC1L3MBTL1TSHR
SCHEMBL3127747 0.91 NOTUM (0.63) NOTUMTSHRALDH1A1MAPTHPGD
SCHEMBL29476005 0.91 NOTUM (0.63) NOTUMTSHRALDH1A1MAPTHPGD
SCHEMBL5795681 0.90 NOTUM (0.57) NOTUMTSHRALDH1A1KMT2AMEN1
SCHEMBL20832607 0.85 RAB9A (0.56) NOTUMRAB9ANPC1L3MBTL1TSHR
SCHEMBL5806132 0.85 NOTUM (0.58) NOTUMRAB9ANPC1TSHRALDH1A1
SCHEMBL30721522 0.82 NOTUM (0.67) NOTUMRAB9ANPC1L3MBTL1TSHR
SCHEMBL5585204 0.82 NOTUM (0.67) NOTUMRAB9ANPC1L3MBTL1TSHR
SCHEMBL21285908 0.81 KDM1A (0.53) NOTUMTSHRALDH1A1KDM1A
SCHEMBL27620869 0.81 ALDH1A1 (0.57) NOTUMRAB9ANPC1L3MBTL1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115353478-A Preparation method of indole compound 南京工业大学 2022-11-18 CN claimed
CN-107098845-A A kind of preparation technology of the nitroindoline of 5 cyano group 6 贵州大学 2017-08-29 CN claimed
US-12422399-B2 Systems, devices, and methods for gas sensing MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2025-09-23 US disclosed
US-12365681-B2 Dihydrobenzimidazolones for medical treatment C4 THERAPEUTICS, INC. (US) 2025-07-22 US disclosed
CN-120077040-A Compounds for SHP2 protein degradation and medical uses thereof 尤比克斯治疗公司 2025-05-30 CN disclosed
CN-119255997-A Modulators of c-MYC mRNA translation and their use in the treatment of cancer 艾尼莫生物科技公司 2025-01-03 CN disclosed
US-20240353369-A1 SYSTEMS, DEVICES, AND METHODS FOR GAS SENSING MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2024-10-24 US disclosed
CN-114380799-B COT modulators and methods of use thereof 吉利德科学公司 2024-10-01 CN disclosed
US-12013367-B2 Monolithic 3D integrated circuit for gas sensing and method of making and system using MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2024-06-18 US disclosed
CN-117917406-A Heterocyclic compounds, process for their preparation and their use 四川科伦博泰生物医药股份有限公司 2024-04-23 CN disclosed
US-20240109889-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2024-04-04 US disclosed
EP-1399445-A2 SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-03-24 EP disclosed
US-6630496-B1 Antiinflammatory agents inhibit phospholipase 2, affecting both protaglandin and leukotriene production; indoles substituted in 2 position by 2,4-dioxo-thiazol-3-yl methylidene GENETICS INSTITUTE LLC 2003-10-07 US disclosed
WO-2002059124-A2 SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2002-08-01 WO disclosed
EP-1062216-A1 INHIBITORS OF PHOSPHOLIPASE A2 GENETICS INSTITUTE, INC. (US) 2000-12-27 EP disclosed
WO-1999043672-A9 INHIBITORS OF PHOSPHOLIPASE A2 GENETICS INST (US) 2000-05-04 WO disclosed
WO-1999043672-A1 INHIBITORS OF PHOSPHOLIPASE A2 GENETICS INSTITUTE, INC. (US) 1999-09-02 WO disclosed
EP-0922028-A1 INHIBITORS OF PHOSPHOLIPASE ENZYMES GENETICS INSTITUTE, INC. (US) 1999-06-16 EP disclosed
CN-1214690-A Specific immunophilin ligands as antiasthmatics and immunosuppressants ASTA MEDICA AG (DE) 1999-04-21 CN disclosed
WO-1998008818-A1 INHIBITORS OF PHOSPHOLIPASE ENZYMES GENETICS INSTITUTE, INC. (US) 1998-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12365681-B2 Dihydrobenzimidazolones for medical treatment CRBN, CUL4A, ADRM1 NOTUM 4088/4885RAB9A 3519/4885NPC1 3010/4885
US-20240109889-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT CRBN, CUL4A, ADRM1 NOTUM 4088/4885RAB9A 3519/4885NPC1 3010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.